Journal of Cancer Research and Clinical Oncology最新文献

{"title":"The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.","authors":"Yilin Shi, Dongpeng Zhao, Zhimin Xiao, Ying Wang, Qincong Feng, Yan Gu","doi":"10.1007/s00432-025-06298-4","DOIUrl":"10.1007/s00432-025-06298-4","url":null,"abstract":"<p><strong>Purpose: </strong>Lung cancer is currently the most common malignant tumor worldwide and one of the leading causes of cancer-related deaths, posing a serious threat to human health. MicroRNAs (miRNAs) are a class of endogenous non-coding small RNA molecules that regulate gene expression and are involved in various biological processes associated with lung cancer. Understanding the mechanisms of lung carcinogenesis and detecting disease biomarkers may enable early diagnosis of lung cancer.</p><p><strong>Methods: </strong>Epithelial-mesenchymal transition (EMT) is a critical biological process through which tumor cells acquire migratory and invasive capabilities, playing an important role in the progression of lung cancer. miRNAs regulate the EMT process in lung cancer cells by targeting transcription factors such as Snail, Slug, and ZEB1/2, as well as modulating signaling pathways including TGF-β and Wnt/β-catenin, thereby enhancing their migratory and invasive abilities.</p><p><strong>Results: </strong>NSCLC has been comprehensively elucidated in terms of its pathogenesis, and the detection and therapeutic approaches targeting miRNAs for NSCLC have been systematically summarized.</p><p><strong>Conclusion: </strong>This review examines the impact of miRNAs on tumor invasiveness through the regulation of key factors or signaling pathways, as well as their potential as biomarkers for the early diagnosis of lung cancer. It provides a theoretical foundation for studying the mechanisms of lung cancer metastasis and developing more precise detection and treatment strategies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"252"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sociodemographic and socioeconomic factors on functional and health-related quality of life outcomes 24 months after radical prostatectomy.","authors":"M Maas, K Funk, V Stühler, S Walz, H Bahlburg, J Hennenlotter, J Bedke, S Aufderklamm, A Stenzl, I Tsaur, Steffen Rausch","doi":"10.1007/s00432-025-06287-7","DOIUrl":"10.1007/s00432-025-06287-7","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>High socioeconomic status (SES) is associated with improved oncological outcomes across various cancer types, including prostate cancer. However, limited evidence exists regarding the impact of SES and lifestyle factors on patient-reported outcomes (PROs), including quality of life (QoL), health status (HS), and functional recovery following radical prostatectomy (RP).</p><p><strong>Materials and methods: </strong>We conducted a retrospective single-center analysis of 327 patients undergoing RP (177 open, 150 robotic-assisted) assessing pre- and postoperative functional outcomes (QoL, HS, erectile function, continence). PROs were evaluated 24 months postoperatively. Correlations with sociodemographic, socioeconomic (ISEI-based SES, marital status, occupational status, hometown size), and lifestyle factors (physical activity, BMI, mental stress) were analyzed.</p><p><strong>Results: </strong>Pathological features of locally advanced tumors correlated negatively with QoL and HS. Higher SES was significantly associated with improved continence, but not with QoL, HS, or erectile function. Pre-existing mental stress negatively affected both continence and HS. Regular physical activity correlated positively with QoL and HS. Multivariable regression confirmed these findings and identified mental stress, SES, partnership and physical activity as independent predictors of PROs.</p><p><strong>Conclusion: </strong>Beyond adverse tumor pathology, mental stress adversely impacts functional recovery and subjective health. In contrast, physical activity and a stable partnership correlate with better PROs. These findings may inform personalized patient counseling to increase postoperative satisfaction.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"245"},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial.","authors":"Anika Kästner, Anna Kron, Leonie Eilers, Anna Spier, Vanessa Mildenberger, Dusan Simic, Stephanie Stock, Florian Kron, Matthias Scheffler, Gerhard Schillinger, Neeltje van den Berg, Jürgen Wolf, Wolfgang Hoffmann","doi":"10.1007/s00432-025-06275-x","DOIUrl":"10.1007/s00432-025-06275-x","url":null,"abstract":"<p><strong>Purpose: </strong>The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.</p><p><strong>Methods: </strong>DigiNet is a prospective, controlled, non-randomized multicenter cohort study including patients with stage IV NSCLC in two study regions (East and West) in Germany. The results of molecular diagnostics and clinical information, along with the entire treatment data are documented in a shared database. A board of lung cancer specialists monitors critical events. Patients digitally complete quality of life questionnaires, with results visualized for physicians. To assess the impact of this personalized digital care, a population-based control group will be identified by matching cohorts within the involved cancer registries. The primary endpoint is OS, and secondary endpoints comprise time on first-line treatment and hospitalization rates. Furthermore, a health economic and business economic evaluation will be conducted. Qualitative interviews with patients and physicians will be performed to assess barriers and facilitating factors for implementing the DigiNet intervention.</p><p><strong>Ethics: </strong>The study protocol was reviewed and approved by the Ethics Committee of the University Hospital of Cologne (21-1521).</p><p><strong>Trial registration: </strong>NCT05818449, registered retrospectively on December 12, 2022.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"244"},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry evaluation and uncertainty analysis of Cobalt-60 HDR brachytherapy for cervical cancer in resource-limited settings.","authors":"Asmaa M El-Doushy, Ehab Marouf Attalla, I H Ibrahim, S M El-Sayed, Ayat M Saadeldin","doi":"10.1007/s00432-025-06280-0","DOIUrl":"10.1007/s00432-025-06280-0","url":null,"abstract":"<p><strong>Background: </strong>High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative. This study aims to evaluate the dosimetric performance and planning uncertainties associated with Co-60 HDR brachytherapy.</p><p><strong>Methods: </strong>A retrospective dosimetric analysis was conducted on 30 patients with FIGO stage IIB-IIIB cervical cancer, eligable for Brachytherapy, were treated using CT-guided intracavitary HDR brachytherapy with Co-60 sources. Treatment plans were assessed for high-risk clinical target volume (HR-CTV) coverage (D90, D80), dose-volume histogram parameters, and organ-at-risk (OAR) doses (D2cc for bladder, rectum, and sigmoid). Plan quality indices including conformity index (COIN), dose homogeneity index (DHI), and dose non-uniformity ratio (DNR) were calculated. Uncertainty analyses accounted for treatment planning system (TPS) variability and applicator positioning.</p><p><strong>Results: </strong>The mean HR-CTV D90 was 6.97 Gy, achieving 99.6% of the prescription dose. The mean D2cc values were 5.73 Gy for bladder (81.9%Rx), 4.72 Gy for rectum (67.4%Rx), and 3.23 Gy for sigmoid, all within acceptable tolerance limits. The mean COIN was 0.292, DHI 0.31, and DNR 0.69, indicating moderate dose conformity and acceptable inhomogeneity. TPS and applicator uncertainties contributed to estimated dose deviations of ± 2% and ± 1 mm, respectively.</p><p><strong>Conclusion: </strong>Cobalt-60 HDR brachytherapy provides clinically acceptable dose coverage and OAR sparing, with dosimetric outcomes comparable to Ir-192. Its longer half-life offers practical advantages for LMICs. Optimization of dose distribution and further validation through Monte Carlo simulations and prospective clinical studies are recommended.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"247"},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of dipeptidyl peptidase 9 improves sorafenib sensitivity by inducing ferroptosis in hepatocellular carcinoma.","authors":"Qing Li, Yang Wang, Jun Zou","doi":"10.1007/s00432-025-06300-z","DOIUrl":"10.1007/s00432-025-06300-z","url":null,"abstract":"<p><strong>Objective: </strong>Dipeptidyl peptidase 9 (DPP9) not only regulates tumor progression and drug sensitivity, but also modifies oxidative stress mediated ferroptosis. This study aimed to investigate the effect of DPP9 inhibition on sorafenib sensitivity and its interaction with ferroptosis in hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>Two HCC cell lines (Huh7 and MHCC-97H) were transfected with DPP9 siRNA, followed by detection of reactive oxygen species (ROS), ferrous iron (Fe²⁺), malondialdehyde (MDA), and ferroptosis-related proteins, and treated by 0-16 μM sorafenib to calculate half-maximal inhibitory concentration (IC₅₀) for sensitivity assessment. Moreover, ferrostatin-1 (Fer-1) was added with or without DPP9 siRNA, followed by the above detections.</p><p><strong>Results: </strong>Inhibition of DPP9 improved sorafenib sensitivity reflected by a lower sorafenib IC₅₀ value, and it increased ROS fluorescence intensity, Fe²⁺ level, and MDA level, which also upregulated ACSL4 expression but downregulated NRF2 and SLC7A11 expressions. Fer-1 treatment decreased ROS fluorescence intensity, Fe²⁺ level, MDA level, and reduced sorafenib sensitivity reflected by a higher sorafenib IC₅₀ value. Moreover, Fer-1 treatment weakened the effect of DPP9 inhibition on ROS fluorescence intensity, Fe²⁺ level, MDA level, most of the ferroptosis-related proteins, and sorafenib sensitivity reflected by sorafenib IC₅₀ value.</p><p><strong>Conclusion: </strong>Inhibition of DPP9 improves sorafenib sensitivity by promoting ferroptosis in HCC, which provides novel evidence for DPP9 as an HCC treatment target synergizing with sorafenib.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"243"},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization.","authors":"Jianfeng Zhou, Pinhao Fang, Zhiwen Liang, Xiaokun Li, Siyuan Luan, Xin Xiao, Yinmin Gu, Qixin Shang, Hanlu Zhang, Yushang Yang, Longqi Chen, Xiaoxi Zeng, Yong Yuan","doi":"10.1007/s00432-025-06313-8","DOIUrl":"10.1007/s00432-025-06313-8","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"246"},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression patterns of plasma microRNAs in patients with cervical cancer from two teaching hospitals in Ghana.","authors":"Helena Quayson, Joseph Humphrey Kofi Bonney, Daniel Sam, Gloria Francisca Nuer-Allornuvor, Roland Osei Saahene, Nicholas Ekow Thomford, Benjamin Amoani, Francis Abrokwah, Karen Pomeyie, Musah Kalaamullah Salisu, Prince Amoah Barnie","doi":"10.1007/s00432-025-06281-z","DOIUrl":"10.1007/s00432-025-06281-z","url":null,"abstract":"<p><strong>Aim: </strong>Early cervical cancer diagnosis is a global challenge that needs to be addressed by the discovery of less invasive diagnostic and prognostic approaches. Circulating miRNAs are stable in plasma and their diagnostic potentials have been elucidated in some cancers. Therefore, in this cross-sectional study, we determined the patterns of expression of 7 selected circulating microRNAs that differ between patients with cervical cancer receiving therapy, patients with cervical not on therapy and healthy females. The goal was to investigate the diagnostic and prognostic potential of these selected miRNAs.</p><p><strong>Methods: </strong>Total RNA was extracted from plasma samples collected from 53 participants recruited from Komfo Anokye Teaching Hospital and the Cape Coast Teaching Hospital, Ghana. Complementary DNA (cDNA) synthesis was performed, followed by quantitative polymerase chain reaction (qPCR) to amplify and quantify the expression levels of the target microRNAs. Expression levels of seven microRNAs-hsa-miR-146a, hsa-miR-29a, hsa-miR-29b, hsa-miR-34a, hsa-miR-233, hsa-miR-155, and hsa-miR-27a were compared among three groups: healthy controls (n = 27), patients with cervical cancer on therapy (n = 13), and those not on therapy (n = 13).</p><p><strong>Results: </strong>miR-155 and miR-27a showed statistically significant differential expression between cancer patients and healthy controls. In addition, miR-29b expression levels differed significantly between stage 4b and stage 4a of patient with cervical cancer undergoing treatment.</p><p><strong>Conclusion: </strong>These findings suggest that circulating plasma miRNAs may serve as non-invasive biomarkers for the early detection of cervical cancer, monitoring disease progression, and evaluating treatment response.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"242"},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on the SERAPHINA study assessing the utilization, efficacy, safety, and quality of life of nab-paclitaxel in patients with advanced HER2-negative breast cancer.","authors":"Kadri Altundag","doi":"10.1007/s00432-025-06292-w","DOIUrl":"10.1007/s00432-025-06292-w","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"241"},"PeriodicalIF":2.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study.","authors":"Simone Rota, Silvia Buriolla, Andrea Franza, Stefano Cavalieri, Cristiana Bergamini, Salvatore Alfieri, Imperia Nuzzolese, Elena Colombo, Arianna Ottini, Benedetta Lombardi Stocchetti, Giacomo Massa, Augusto Caraceni, Lisa Licitra, Carlo Resteghini","doi":"10.1007/s00432-025-06297-5","DOIUrl":"10.1007/s00432-025-06297-5","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"240"},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary.","authors":"Yasutaka Tono, Koshi Sukeno, Akira Tsunoda, Mariko Okayama, Hiroki Oka, Hiroyasu Oda, Kanako Saito, Yoshiki Yamashita, Masayasu Taniguchi, Makoto Ikejiri, Satoshi Tamaru, Masaki Tanabe, Hiroshi Imai, Masatoshi Watanabe, Toshiro Mizuno","doi":"10.1007/s00432-025-06293-9","DOIUrl":"10.1007/s00432-025-06293-9","url":null,"abstract":"<p><strong>Purpose: </strong>The estimation of the primary site is crucial when considering chemotherapy regimens in cancer of unknown primary (CUP). The task is particularly challenging for poorly differentiated or undifferentiated carcinoma, or unknown histological tumors with unknown primary (U-CUP). Instead of site-specific chemotherapy, a biomarker-guided therapy using genomic testing is required to predict the efficacy of molecular-targeted agents and immune checkpoint inhibitors (ICI). We focused on inactivating the SWI/SNF complex, a chromatin regulatory complex. We investigated the clinical features of CUP with SWI/SNF chromatin remodeling abnormalities and examined whether SWI/SNF chromatin remodeling abnormalities are a predictive marker of ICI efficacy.</p><p><strong>Methods: </strong>A multi-institutional observational study was conducted between January 2009 and March 2022. Immunostaining for SMARCA2, SMARCA4, and SMARCB1 was performed on 80 patients with CUP. Nextgeneration sequencing analysis was conducted on SMARCA4, SMARCA2, SMARCB1, ARID1A, PBRM1, ARID2, and ARID1B, which are frequent SWI/SNF-associated genes, in 32 patients with CUP.</p><p><strong>Results: </strong>Immunohistochemistry revealed that the loss of SMARCA4 protein was most frequent, occurring in 14 patients (17.5%). Among the 32 patients with CUP, SMARCA4 mutations were detected in 50% (n = 16) of patients. In 6 cases with truncating mutations, immunostaining revealed protein loss. U-CUP cases were associated with loss of SMARCA4 protein. In SMARCA4-deficient patients, overall survival was prolonged in the ICI-containing regimen group (p = 0.033).</p><p><strong>Conclusion: </strong>This study demonstrated SWI/SNF chromatin remodeling abnormalities in CUP and the association between SMARCA4 deficiency and U-CUP. It suggests a potential strategy for selecting an ICI regimen for CUP, particularly U-CUP, with SMARCA4 deficiency.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"238"},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}